Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Cash from Operations for 10 consecutive years, with 291000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 12.35% to 291000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1068000.0 through Dec 2025, up 4.56% year-over-year, with the annual reading at 1068000.0 for FY2025, 4.56% up from the prior year.
  • Cash from Operations hit 291000.0 in Q4 2025 for Guided Therapeutics, down from 277000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 159000.0 in Q4 2021 to a low of 739000.0 in Q3 2021.
  • Historically, Cash from Operations has averaged 350200.0 across 5 years, with a median of 334000.0 in 2023.
  • Biggest five-year swings in Cash from Operations: skyrocketed 148.04% in 2021 and later crashed 313.21% in 2022.
  • Year by year, Cash from Operations stood at 159000.0 in 2021, then crashed by 313.21% to 339000.0 in 2022, then grew by 0.88% to 336000.0 in 2023, then increased by 1.19% to 332000.0 in 2024, then rose by 12.35% to 291000.0 in 2025.
  • Business Quant data shows Cash from Operations for GTHP at 291000.0 in Q4 2025, 277000.0 in Q3 2025, and 169000.0 in Q2 2025.